We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00186680
First Posted: September 16, 2005
Last Update Posted: March 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Stanford University
September 14, 2005
September 16, 2005
March 2, 2010
September 1996
June 2005   (Final data collection date for primary outcome measure)
Feasibility and safety
Feasiblity and safety
Complete list of historical versions of study NCT00186680 on ClinicalTrials.gov Archive Site
  • efficiency of mobilization
  • tumor contamination
  • - efficiency of mobilization
  • - tumor contamination
Not Provided
Not Provided
 
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment
Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
Procedure: high dose chemo then auto hematopoietic cell transplant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
99
June 2005
June 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:- stage IV breast cancer

  • primary breast cancer does not express CD34+
  • adequate organ function
  • no evidence of active infection

Exclusion Criteria:- chemotherapy within 4 weeks

- CNS disease

Sexes Eligible for Study: All
19 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00186680
BMT86
BMT86
Not Provided
Not Provided
Not Provided
Ginna Laport, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Ginna Laport Stanford University
Stanford University
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP